


## Newsletter

December 2021 Issue No.12

Bringing you the latest news and developments in CLL

Helpline: 0800 977 4396

---



### **Covid-19 Update**

#### **An important clarification**

#### **Monoclonal antibody treatment for Covid-19**

In the last newsletter we stated that NHS England had authorised monoclonal antibody treatment at home for certain patients, including those with CLL. Previously this was only available after hospital admission.

**We have learnt from members that not all health providers are aware of this important development, and we are giving links below to the relevant announcements for England and Scotland. You may wish to use these documents to clarify the position if you need to contact your health provider should you become infected by Covid.**

Please note that Wales and Northern Ireland may follow different guidance.

**Key points:**

- Directive issued on 6 December and is effective from 18 December
- Patient must have a positive PCR test for Covid
- Patient must be in one of the specified high-risk categories, which **includes CLL, whether you have received treatment or not.**

**You can find the NHS announcements here:**

- [CEM\\_CMO\\_2021\\_020.pdf](#)
  - [nMABs\\_AV\\_Community\\_RPS.pdf](#)
  - <https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103184>
- 

**Other Covid News:**

The recent announcement that a new and potentially more transmissible variant of Covid 19 has been detected has caused concern amongst patients. Although details are still very uncertain, there is sufficient information for the UK government to bring forward booster vaccination plans.

The picture will become clearer in about two weeks when laboratories around the world have concluded their tests, but we have summarised what we know so far on our website [here](#). Please take a look. We'll update it as more details become available.

**Covid restrictions**

**The UK government has just announced new Covid restrictions for England. You can find details of these [here](#). Note that different advice may apply in devolved countries.**

---